{"analyses":[{"groupIds":["OG001","OG002"],"nonInferiorityComment":"Other = Kaplan Meier","nonInferiorityType":"OTHER","pValue":"0.43","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.6","upperLimit":"15.7","value":"10.2"},{"groupId":"OG001","lowerLimit":"4.8","upperLimit":"21.9","value":"10.3"},{"groupId":"OG002","lowerLimit":"6.0","upperLimit":"26.0","value":"9.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"PFS is defined as time from day 1 of pomalidomide therapy until progression requiring a change in therapy, estimated using the Kaplan-Meier method. Progression was assessed using the Modified Acquired Immunodeficiency Syndrome (AIDS) Clinical Trials Group criteria. Progressive disease (PD) involved a 25% or greater increase in total lesions, nodular lesion, or area of the five indicator lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"All participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG000","title":"All Participants"},{"description":"HIV positive participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG001","title":"HIV Positive Participants"},{"description":"HIV negative participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG002","title":"HIV Negative Participants"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"time from day 1 of pomalidomide therapy until progression requiring a change in therapy, an average of 9.97 months","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}